Tracking how psoriasis responds to new advanced treatments
Part of Skin clinical trials.
This study follows patients with moderate to severe psoriasis who are starting a new advanced medication for the first time. Researchers will track how well the treatment works early on to understand what helps different patients improve.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have moderate to severe plaque psoriasis (the most common type) diagnosed by a doctor
- You are starting a new advanced psoriasis medication for the first time
- You will receive at least one dose of the new medication within 2 weeks of enrolling
- You are not currently in another psoriasis study (like the CorEvitas PSO Registry)
- You are willing to give informed consent and participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people starting a new advanced psoriasis treatment to see how well it works over 16 weeks. You'll have three office visits with your dermatologist, and researchers will track your skin improvement to help understand which treatments work best for different patients.
This registry collects information from adults with psoriasis to better understand how psoriasis affects people and how treatments are used in real life. It may help future research and improve knowledge about treatment patterns and outcomes.
This study looks at how well two common plaque psoriasis medicines—deucravacitinib and apremilast—work in everyday care. It may help researchers understand which option performs better in real patients outside of a traditional drug trial.
This trial is a registry that collects information from adults with plaque psoriasis or psoriatic arthritis who are starting a new biologic or other systemic treatment. It helps researchers understand how these treatments are used in real life and what outcomes they may have.
This study keeps track of how people with moderate-to-severe psoriasis do over time while using Siliq or other approved treatments. It may help researchers understand how treatments compare in real life.
This study is a psoriasis registry that records real-world information about people starting a systemic (whole-body) treatment for the first time. It helps doctors understand how these treatments work in everyday care and may improve future treatment decisions.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.